Animal Toxicology Studies on the Male Reproductive Effects of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin: Data Analysis and Health Effects Evaluation

Tongtong Zhang†, Xiang Zhou†, Xiaohan Ren†, Xu Zhang†, Jiajin Wu†, Shangqian Wang1,2* and Zengjun Wang1,3*

1 Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, 2 State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, China, 3 Department of Urology, The First People’s Hospital of Xuzhou City, Xuzhou, China

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a well-known environmental poison that exist in the environment for many years. However, its effect on the male reproductive system has not been clearly stated. We conducted a meta-analysis of the effect of TCDD on the male reproductive system of rodents about TCDD. Results showed that TCDD exposure reduced the testis weight (weighted mean difference [WMD]: −0.035, 95% confidence interval [CI]: −0.046 to −0.025), sperm count (WMD: −35, 95% CI: −42.980 to −27.019), and blood testosterone concentration (WMD: −0.171, 95% CI: −0.269 to −0.073). According to our research results, TCDD can cause damage to the male reproductive system of rodents through direct or indirect exposure. In order to further explore the potential hazards of TCDD to humans, more human-related research needs to be carried out.

Keywords: reproductive toxicity, semen parameter, dioxin, environmental pollutant, meta-analysis

1 INTRODUCTION

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is characterized by white crystals or tan crystalline powder. TCDD is a highly toxic substance to mammals. Numerous studies suggested that the exposure to TCDD enhances the incidence rate of several kinds of malignant neoplasms in humans, and WHO declared that TCDD is a human carcinogen (NCBI, PubChem Database). TCDD is a dioxin-like compound and considered the most persistent and the most potent endocrine disruptor among other dioxin-like congeners (1, 2). Among the 210 congeners, TCDD is considered to be the most toxic (3). As an unwanted byproduct produced during the synthesis of chlorinated hydrocarbons, manufacturing pesticides, burning household waste, and forest fires, TCDD is found in the soil, air, water, and in daily foods, like fish, meat, and dairy products (4, 5). Given its extreme resistance to degradation, high lipophilicity, and extreme stability (half-life in humans up to 7–9 years), TCDD accumulates in soil and water, enters the food chain, and ingested by humans (2, 6). TCDD has gotten its great disrepute from the use of Agent Orange, a herbicide applied during
the Vietnam War (August 1965 to February 1971), of which TCDD is a side product. Another famous public safety incidence has occurred in July 1976, when a chemical plant has exploded near Seveso, Italy, known as Seveso Disaster, and exposed local residents to the highest known levels of TCDD, which has resulted in high incidence of tooth malformation, low semen quality, and dysregulated cell immunity (6).

TCDD is a recognized environmental poison. The sources of TCDD include human industrial production activities and natural processes, such as volcanic eruptions and forest fires. TCDD has been identified as a human carcinogen and can increase the incidence of many malignant tumors. Recently, researchers have begun to pay attention to the possible damage of TCDD to the human reproductive system (https://www.who.int/news-room/fact-sheets/detail/dioxins-and-their-effects-on-human-health). Considering the insufficient evidence in human research, the effect of TCDD on the human male reproductive system remains unknown. A systematic quantitative analysis of the existing animal research data is conducted to provide indirect evidence for anthropological research.

Nowadays, male reproductive disorders have been well noticed and become a worldwide problem. The sperm counts in young men significantly decline over the past few years, and the rates of male reproductive cancer are on the rise in many countries (7). The incidence of testicular cancer, cryptorchidism, and hypospadias continues to increase. By contrast, the quality of semen is declining (8). In 1938–1990, the sperm concentration has decreased nearly thrice with increasing genitourinary abnormalities, such as testicular malignancy and hypospadias (9). According to the research of Agarwal, A., et al., at least 30,000,000 men around the world are suffering from infertility (10). Current studies suggested that environmental pollutant exposures of the fetal testis and their toxicity effect on the adult endocrine system may act as the foremost factors in the observed phenomena (11). With the fast development of industry and civilization, environmental toxin-induced male reproductive disorders are becoming prominent.

The potential adverse effects of TCDD on males have been investigated by human epidemiological studies and nonhuman animal studies (6, 12–16). The gestational exposure of TCDD is reported to decrease the body weight of male offspring, but a 30-year cohort study found no significant association between male offspring birthweight changes and in utero TCDD exposure (16–18). A dosage of 0.7 µg/kg TCDD exposure on gestational day 15 reduces the anogenital distance (AGD) of male offspring on postnatal days 1 and 4, whereas 1 µg/kg TCDD exposure on gestational day 15 shows no apparent effect on male AGD on postnatal day 1 in another study (15, 19). The oral dosage of 1 µg/kg TCDD is reported to induce low testes weight, but these results are still inconsistent with other studies (20, 21). Considering that the conclusions of animal studies are not consistent and that the evidence of human studies is inadequate, we decided to conduct a systematic review with meta-analysis to synthesize the outcomes of animal experiments to arouse people’s warnings and provide ideas for the future in-depth research of TCDD or related materials.

2 METHODS
2.1 Topic Statement and Problem Formulation

The topic statement and Population, Exposure, Comparator, and Outcome (PECO) formulation of our systematic review were based on the handbook (22) developed by the National Toxicology Program’s Office of Health Assessment and Translation (OHAT) for animal experimental studies (Supplementary Table 0).

2.2 Literature Search Strategy and Inclusion Criteria

Pubmed, Embase, Cochrane library, PROSPERO, and Google were searched using terms like “TCDD”, “meta”, or “systematic review” to find protocols or published systematic reviews similar with our topic to avoid duplication of work. Afterward, a systematic literature search process was performed in Pubmed, Embase, and Cochrane library on March 7, 2020. The search strategy was developed by combining the individual PECO parts as the formula: (1. species) AND (2. toxin) AND (3. outcomes).

The inclusion and the exclusion criteria were developed to select eligible studies.

The inclusion criteria were as follows:
1) studies that have been peer reviewed,
2) studies in English,
3) studies on controlled animal TCDD exposure experiments,
4) studies with clear species limited to rat or mouse,
5) studies on male reproductive outcomes.

The exclusion criteria were as follows:
1) studies that were not original research articles,
2) studies without full text,
3) studies without male reproductive outcomes,
4) studies investigating neither rat nor mouse species,
5) studies with useless or unclear extractable data.

2.3 Literature Selection

Studies were screened by two researchers. The search outcomes were pooled together into the reference management software (EndNote X7, Thomson Scientific) to find potential duplications. Two researchers individually screened the search result in accordance with the inclusion and the exclusion criteria. During the first step, the title and abstract of each search result were browsed in accordance with the inclusion criteria to determine the potential eligible studies. Disagreements between the researchers about whether an article should be included were resolved by reviewing the full-text article.

2.4 Risk of Bias Assessment of Included Studies

The RoB of all included studies was assessed by evaluating the 11 questions for animal experimental study in accordance with the
OHHAT handbook (22) for animal studies. Briefly, a reviewer independently read each article and answered the 11 RoB questions on the basis of the contents of the article. The response options for each RoB question were Definitely Low (green, ++) if the included study showed direct evidence of low RoB practices, Probably Low (light green, +) if the included study showed indirect evidence of low RoB practices or may not cause significant bias, Probably High (light red, −) if the included study showed indirect evidence of high RoB practices or did not report relevant RoB questions, and Definitely High (red, −−) if the included study showed direct evidence of high RoB practices. Three key elements (i.e., randomization, experimental conditions, and blinding during study) were considered more important than other elements because these elements may seriously affect the confidence of outcomes. The evaluation was conducted twice. The first time was in reverse order of publication time, and the second time was in positive order of publication time to avoid inconsistencies in the evaluation results due to the order of reading. We displayed our assessment outcomes imitating the table developed by the OHAT book (22).

2.5 Data Extraction
Data elements were extracted for analyses in terms of number of animals (\(n\)), means (\(m\)), standard deviation (SD) or standard error (SE), life stage of outcome assessment, life stage of dosage administration, and general information (such as the title, publication time, and region of studies). SE data cannot be directly applied into the meta-analysis. Thus, the outcomes displayed as SE were transformed into SD in accordance with the formula: \(SD = SE \times \sqrt{n}\) where \(n\) is the sample size for the following quantitative analysis. The data in tables and text were extracted directly. Data from figures were indirectly extracted using a graph digitizer software (GetData Graph Digitizer, Version 2.25, software available at http://getdata-graph-digitizer.com/download.php).

2.6 Data Standardization
Eighteen outcomes, including more than five articles, were subjected to meta-analysis. The design of the animal studies was different in the selection of animal strains, administration methods, and exposure time before the quantitative evaluation. Thus, the data were artificially standardized to prevent the data from being too discrete. The units of all outcomes were standardized (e.g., 100 ng/kg was standardized into 0.1 µg/kg). Thus, WMD rather than SMD was applied.

1. All strains of rats or mice were set as standard species “rat” or “mouse” individually.
   a) Rat represents Sprague Dawley, LE, Albino, or Wistar rat or any strain of rat species.
   b) Mouse represents CD-1 or C57BL/6 mouse or any strain of mouse species.
2. Exposure windows were standardized into five periods:
   a) Pregestational: period before maternal gestational (< G0),
   b) Gestational: period from the first day pregnancy was detected by performing vaginal smear or observing vaginal plug (G0, P0),
   c) Lactational: period from the first day of birth to weaning [P0, P21),
   d) Pubertal: period from weaning to postnatal day 56 [P21, P56),
   e) Mature: period after postnatal day 56 (> P56).
3. Administration was classified into three methods.
   a) i.p. represents intraperitoneal injection,
   b) i.h. represents hypodermic injection,
   c) p.o. represents peroral gavage.
4. Outcomes were standardized and classified into four groups:
   a) sperm count (\(\times 10^6\)), daily sperm production (\(\times 10^6\)), sperm motility (%), and abnormal sperm (%),
   b) serum testosterone (ng/ml), AGD (mm), and relative AGD (% body length),
   c) ventral prostate weight (g), prostate weight (g), relative ventral prostate weight (% body weight), seminal vesicle weight (g), and relative seminal vesicle weight (% body weight),
   d) testis weight (g), testes weight (g), relative testis weight (% body weight), relative testes weight (% body weight), epididymis weight (g), and relative epididymis weight (% body weight).
5. Dosage units were standardized as µg/kg, and dosage levels were divided into four groups
   a) Low Level: (< 0.1 µg/kg),
   b) Relative Low Level: [0.1 µg, 1 µg),
   c) Relative High Level: [1 µg, 10 µg),
   d) High Level: (>10 µg).

2.7 Meta-Analysis
The meta-analysis was performed for outcomes if more than five studies were included. Effect sizes were generated by calculating the standardized (SMD) or the weighted (WMD) mean difference and 95% confidence interval (CI) of each intervention–control comparison. Individual SMDs or WMDs were pooled to reach a conclusion. The heterogeneity between each study was assessed using the \(I^2\) statistics, and any degree of heterogeneity was acceptable due to the anticipated high heterogeneity of animal studies. The outcomes of heterogeneity assessment were defined into three groups, including low \((I^2 < 50\%)\), moderate \((50\% \leq I^2 < 75\%)\), and high \((I^2 \geq 75\%)\) level. The fixed-effects model was applied if the heterogeneity level between studies was low or moderate, and the random-effects model was used if the heterogeneity level between studies was high. Stratified analysis for subtitles, such as species, exposure window, and dosage, was performed if more than three independent studies were included. Calculated \(p\)-values < 0.05 indicated that the outcomes were statistically significant. If the effect between subgroups significantly differed with each other in the subgroup analysis, the subgroup was explained partly as the reason of heterogeneity. The Egger’s test was used to detect publication bias. If significant publication bias was detected, comparisons with small weights were excluded to observe the change in the effect size after exclusion, and the degree of effect of publication bias on the conclusion was judged on the basis of the amount of excluded data and the change in effect size. Statistical analysis was conducted using the statistical software STATA.
2.8 Confidence of Evidence Assessment

Confidence assessment reflects the credibility of the association between exposure to specific substances and corresponding human health outcomes. For each given outcome, the confidence rating was performed by considering the strengths and weaknesses in a series of human or animal studies that contribute to the body of evidence. The OHAT method for confidence of evidence assessment was applied in our analysis to judge and rate the confidence in the body of evidence on each outcome and conclude the level of health effect of each evidence. “High Confidence” indicates that future studies are not likely to change current conclusions, and “Very Low Confidence” indicates that future studies are very likely to change current conclusions (22). Briefly, for each outcome, initial confidence was set in accordance with four features (namely, controlled exposure, exposure prior to outcome, individual outcome data, and comparison group used), and the factors that may increase (i.e., magnitude, dose response, residual confounding, and consistency across species) and decrease (i.e., RoB, unexplained inconsistency, indirectness, imprecision, and publication bias) the level of confidence were considered. Disagreements were discussed by all reviewers. Initial confidence was upgraded and downgraded in accordance with the factors mentioned above to generate the final level of confidence (i.e., high, moderate, low, or very low) (22) and then transformed into human health effect levels (i.e., high, moderate, low, or inadequate).

3 RESULTS

3.1 Search Results and Study Characteristics

The systematic literature search was performed using the PECO statement and generated 3246 studies after finding duplication. After screening, a total of 55 studies (12–15, 19–21, 23–70) passed the inclusion criteria for data extraction. The literature selection process is displayed as the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (StataSE12.0, Texas, USA, software available at https://www.stata.com/).

28 Confidence of Evidence Assessment

Confidence assessment reflects the credibility of the association between exposure to specific substances and corresponding human health outcomes. For each given outcome, the confidence rating was performed by considering the strengths and weaknesses in a series of human or animal studies that contribute to the body of evidence. The OHAT method for confidence of evidence assessment was applied in our analysis to judge and rate the confidence in the body of evidence on each outcome and conclude the level of health effect of each evidence. “High Confidence” indicates that future studies are not likely to change current conclusions, and “Very Low Confidence” indicates that future studies are very likely to change current conclusions (22). Briefly, for each outcome, initial confidence was set in accordance with four features (namely, controlled exposure, exposure prior to outcome, individual outcome data, and comparison group used), and the factors that may increase (i.e., magnitude, dose response, residual confounding, and consistency across species) and decrease (i.e., RoB, unexplained inconsistency, indirectness, imprecision, and publication bias) the level of confidence were considered. Disagreements were discussed by all reviewers. Initial confidence was upgraded and downgraded in accordance with the factors mentioned above to generate the final level of confidence (i.e., high, moderate, low, or very low) (22) and then transformed into human health effect levels (i.e., high, moderate, low, or inadequate).

3.2 Assessment of RoB

In accordance with the recommendations of the OHAT handbook (22), the outcomes of RoB were assessed (Table 2). Most literature answered “probably high risk” at least one of three key questions. “Allocation concealment” was not mentioned in all the included literature and was marked as “unreported” and translated into “probably high risk”. Regarding the randomness of experimental design, some studies mentioned “randomization” but did not give a detailed explanation of how they performed randomization (e.g., random number table and systematic sampling) and rated as “probably low risk”. In terms of the “experimental conditions”, most of the documents described the details of the animal’s circadian rhythm, food and drinking water, and room temperature. However, detailed questions, such as the height of the animal cages from the ground that had not been mentioned, remained and the evaluation of “definitely low risk” should be conservative. Thus, these studies were rated as “probably low risk”. According to the OHAT handbook, the quality of the literature was stratified. Two articles (64, 67) were classified as tier3 because the answers to the three key questions were all “probably high risk”, and the rest of the documents were classified as tier2. The outcomes of stratification were used to evaluate the confidence level in the later stage. The results of RoB are shown in Table 2.

3.3 Meta-Analysis

3.3.1 Sperm Parameters

Sperm count was available from 62 comparisons provided by 21 studies (Figure 2A). The heterogeneity of the data was high ($I^2 = 99.5\%$, $p = 0.000$). The sperm counts of rats and mice were examined. The exposure time spanned the life stage from prepregnancy to maturity, and the four levels of dosage were evaluated. The pooled WMD was $−35$ with 95% CI of $−42.980$ to $−27.019$ (Table 3A). Daily sperm production was also inversely affected in accordance with the data from 12 studies. The pooled WMD from 54 comparisons was $−0.202$ with 95% CI of $−0.254$ to $−0.150$ and $I^2$ of 97.3% ($p = 0.000$). The relative forest plots and data are shown in Figure 2B and Table 3B, respectively.

In addition to the negative effect on sperm quantity-related parameter, low sperm quality was related to TCDD exposure. The percentage of sperm motility data from nine studies suggested that TCDD exposure significantly reduced the rats’ sperm motility, and the pooled WMD was $−7.365$. The intrastudy heterogeneity of this indicator was slightly reduced compared with other indicators ($I^2 = 89.3\%$). Similarly, the percentage of the abnormal sperm of rats increased after TCDD exposure, and its pooled WMD was $3.142$ with 95% CI of 1.632 to 4.653. High heterogeneity was also detected among comparisons ($I^2 = 94.3\%$). The relative forest plots and data are shown in Supplementary Figures 1A, B and Supplementary Tables 1A, B.
3.3.2 Testosterone and AGD
Twenty studies reported plasma testosterone concentration indicators after TCDD exposure. A total of 62 comparisons were extracted and included in the quantitative analysis. Except one study, which was a mouse study, all other studies were rat studies. The time windows of exposure were from prepregnancy to adulthood (Figure 2C). The overall effect was negative. The pooled WMD was $-0.171$ with $95\%$ CI of $-0.269$ to $-0.073$. High heterogeneity was also detected ($I^2 = 96.6\%$, $p = 0.000$). Data are shown in Table 3C.

AGD is an efficient parameter in the determination of intrauterine exposure to endocrine-disrupting chemicals and an effective tool in the investigation of in utero androgen production (71). AGD data were available in 12 studies, generating 41 comparisons focusing on pregnancy and lactation exposure, and the dosage level ranged from low to relatively high (Supplementary Figure 1C and Supplementary Table 2C). The overall pooled WMD was $-0.536$ with $95\%$ CI of $-0.659$ to $-0.414$, and high heterogeneity was also detected ($I^2 = 96.7\%$, $p = 0.000$). Relative forest plots and data are shown in Figure 2D and Table 3D, respectively.

3.3.3 Seminal Vesicle and Prostate Gland
A total of 66 pairs of comparisons focusing on ventral prostate weight were extracted from the included literature (i.e., rat and mouse studies). The effects of TCDD exposure from pregnancy to adulthood were studied, but very few studies were available on pubertal and lactational exposures, with only one comparison individually. The pooled WMD of the ventral prostate weight was $-0.022$ with $95\%$ CI of $-0.027$ to $-0.017$ and high heterogeneity ($I^2 = 96.7\%$, $p = 0.000$). Relative forest plots and data are shown in Figure 2D and Table 3D, respectively.

The data on the weight of the seminal vesicles were extracted from 15 studies including 57 comparisons, but the data from mouse studies were not available in any study. The exposure windows spanned the gestation to mature life stage, and the effect of four dosage levels were examined. The pooled WMD was $-0.041$ with $95\%$ CI of $-0.051$ to $-0.032$, and $I^2$ was $94.8\%$ ($p = 0.000$). The relative forest plots and data are shown in Supplementary Figure 1E and Supplementary Table 2E, respectively.

In addition, other data associated with prostate and seminal vesicle were quantitatively analyzed. The forest plots and data are available in Supplementary Figures 1F, 2A and Supplementary Tables 2F, 3A, B.
| Study | Region | Species | Doses (ug/kg) | Exposure Stage | Assessment Stage | Administration | Indicators |
|-------|--------|---------|--------------|----------------|-----------------|----------------|------------|
| Pohjanvirta, R., et al. (1987) (23) | USA | Han/Wistar rat | 0, 125, 250, 375, 500, 625, 750, 1000, 1400 | Mature | Mature | i.p. | a, g |
| Al-Bayati, Z. A. F., et al. (1988) (24) | USA | SD rat | 0, 40 | Pubertal | Pubertal | p.o. | a, c |
| Chahoud, I., et al. (1989) (25) | Germany | Wistar rat | 0, 0.388 | Pubertal | Mature | i.h. | a, c |
| Kleeman, J. M., et al. (1990) (26) | USA | SD rat | 0, 100 | Mature | Mature | p.o. | g, k |
| Chahoud, I., et al. (1992) (27) | Germany | Wistar rat | 0, 0.5, 1, 3, 5 | Mature | Mature | i.h. | a |
| Johnson, L., et al. (1992) (28) | USA | SD rat | 0, 0.064, 0.16, 0.4, 1 | Gestational | Mature | i.p. | a, e, k, n, o |
| Mably, T. A., et al. (1992) (29) | USA | SD rat | 0, 0.5, 1, 3, 5 | Gestational | Mature | p.o. | b, e, n, o, q, r |
| Mably, T. A., et al. (1992) (30) | USA | SD rat | 0, 0.064, 0.16, 0.4, 1 | Gestational | Mature | p.o. | g, k, l, m, p |
| Bjerke, D. L. and R. E. Peterson (1994) (21) | USA | SD rat | 0, 1 | Gestational | Lactational | p.o. | b, e, g, l, m, n, p |
| Bjerke, D. L., et al. (1994) (19) | USA | SD rat | 0, 0.7 | Gestational | Lactational | p.o. | b, e, l, m |
| Gray, L. E., Jr., et al. (1995) (31) | USA | LE Hooded rat | 0, 0.05, 0.2, 0.8 | Gestational | Pubertal | p.o. | b, e, g, n, o, p |
| Theobald, H. M. and R. E. Peterson (1997) (35) | USA | CD-1 mouse | 0, 15, 30, 60 | Gestational | Pubertal | p.o. | a, e, g, n, o |
| Cooke, G. M., et al. (1998) (36) | Canada | SD rat | 0, 0.2, 1 | Gestational | Lactational, Late lactational | p.o. | a, h |
| el-Sabawwy, F., et al. (1998) (37) | USA | SD rat | 0, 5 | Pubertal | Mature | p.o. | a, o |
| Faqi, A. S., et al. (1998) (38) | Germany | Wistar rat | 0, 0.005, 0.012, 0.06 | Pregestational | Mature | i.h. | c, f, j, n, o, p, s |
| Roman, B. L., et al. (1999) (39) | USA | SD rat | 0, 1 | Gestational | Mature | p.o. | n, o, k |
| Sommer, R. J., et al. (1999) (40) | USA | SD rat | 0, 1 | Gestational | Lactational, Pubertal | p.o. | k |
| Wilker, C., et al. (1996) (41) | USA | SD rat | 0, 0.5, 1, 2 | Gestational | Mature | p.o. | a, e, f, n, o |
| Roman, B. L., et al. (1998) (39) | USA | SD rat | 0, 1 | Gestational | Mature | p.o. | a, e, g, n, o |
| Kang, K. S., et al. (2000) (41) | Korea | SD rat | 0, 10 | Pubertal | Mature | i.p. | a, g, n |
| Lin, T. M., et al. (2001) (42) | USA | C57BL/6 mouse | 0, 5 | Gestational | Mature | p.o. | a, c, e, f, n, o |
| Latchoumycandane, C., et al. (2002) (43) | India | Wistar rat | 0, 0.001, 0.01, 0.1 | Gestational | Pubertal | p.o. | a, c, e, f, g, i, k, s |
| Latchoumycandane, C. and P. P. Mathur (2002) (44) | India | Wistar rat | 0, 0.001, 0.01, 0.1 | Gestational | Pubertal | p.o. | a, e, g, k, o |
| Ohsako, S., et al. (2002) (45) | Japan | SD rat | 0, 1 | Gestational, Lactational | Mature | p.o., i.h. | b, d, e, f, g, i, k, m, n, o |
| Kwon, Y. I., et al. (2004) (46) | Korea | C57BL/6 mouse | 0, 27.5 | Pubertal | Mature | i.h. | a, p |
| El-Tawil, O. S. and E. M. Elsaieed (2005) (47) | Egypt | SD rat | 0, 0.05, 0.1, 0.2 | Mature | Mature | p.o. | c, f, j, n, q, r, s |
| Ikeda, M., et al. (2005) (48) | Japan | SD rat | 0, 0.2, 0.8 | Gestational | Lactational | p.o. | l, p |
| Ikeda, M., et al. (2005) (49) | Japan | SD rat | 0, 0.08 | Gestational | Lactational | p.o. | d, l |
| Myfyhmäki, S. A., et al. (2005) (50) | Finland | SD rat | 0, 0.04, 0.2, 1 | Gestational | Lactational | p.o. | a, c, p |
| Yamano, Y., et al. (2005) (51) | Japan | SD rat | 0, 0.3, 1 | Lactational | Mature | i.h. | a, n |
| Yonemoto, J., et al. (2005) (52) | Japan | LE Hooded rat | 0, 0.0125, 0.05, 0.2, 0.8 | Gestational | Pubertal, Mature | p.o. | b, d, e, f, g, i, k, s |

(Continued)
### 3.3.4 Testis and Epididymis

A total of 25 articles generating 97 comparisons provided testis weight data. Rat and mouse experiments were performed. The exposure period of the studies ranged from pregnancy to adulthood, and the dosage levels were from low to high. The pooled WMD was $-0.035$ with $95\%$ CI of $-0.046$ to $-0.024$ and $I^2$ of $98.2\%$ ($p = 0.000$), suggesting that TCDD exposure may reduce testicular weight but with high heterogeneity. The forest plots and data are shown in Supplementary Figure 2C and Supplementary Table 2C, respectively.

The epididymis weight data were extracted in 22 articles, and 94 pairs of comparisons from rats and mice were included in the analysis. The exposure phase also covered life stages from pregnancy to adulthood, but only one comparison of pubertal exposure data was extracted. The dosage levels of TCDD ranged from low to high. The pooled WMD of the total effect was $-0.029$ with the $95\%$ CI of $-0.034$ to $-0.023$, and the heterogeneity between studies was strong ($I^2 = 95.1\%$, $p = 0.000$), suggesting that TCDD exposure may cause the atrophy of epididymis. The forest plots and data are shown in Supplementary Figure 2D and Supplementary Table 3D, respectively.

In addition to the absolute weight data of the epididymis and testis, the testes weight and the relative weight of the above two organs were analyzed. The forest plots and their details were shown in Supplementary Figures 3A–D and Supplementary Tables 4A–D.

### 3.3.5 Subgroup Analysis

Subgroup analysis was performed to discover the effects of exposure on related indicators under different subcategories. Each indicator was further analyzed in terms of species, exposure time window, and dosage level. Subgroup analysis revealed that some of the conclusions may have cross-species consistency (e.g., testis weight) and found differences in sensitivity of different tissues and organs to TCDD at different time windows. The relative outcomes of subgroup analysis and detailed data were classified by indicator (Supplementary Figures 4–21 and Supplementary Tables 5–22). After subgroup analysis, if the heterogeneity of the subgroup is lower than the original group and exceeds a level, it is considered that the source of the heterogeneity of the original group is related to the classification of the subgroup. If the heterogeneity of the subgroup is still high and does not differ from the original group by more than one level, it is considered that the source of the heterogeneity is related to the experimental design of the included study.

### 3.4 Evaluation of Publication Bias

The Egger’s test was applied to determine the publication bias. If the $95\%$ CI did not include 0 through the Egger’s test, significant publication bias was detected (Supplementary Figure 22). The Egger’s test suggested that significant publication bias was detected in 10 outcomes. After gradually excluding comparisons with small weights, the indicators with publication bias were divided into two categories: 1. The publication bias can be neutralized by eliminating the comparisons with small weights, and the conclusion remains unchanged; and 2. The publication bias can be neutralized by eliminating the comparisons with small weights, but the conclusion changes or publication bias exists after 50% of comparisons with small weight are excluded.
3.5 Confidence Rating

Given that all included studies were animal intervention studies, the initial level of evidence was rated as the highest level. Because the data of each outcome were all or mostly from the tier2 study category, a downgrade was performed in the RoB. The forest plots of the relative testis weight (% body weight) and daily sperm production (×10⁶) were discrete and had high I². Thus, the rate of these two outcomes should be degraded to “Unexplained Inconsistency.” The publication biases of relative testis weight (% body weight), AGD (mm), seminal vesicle weight (g), and relative seminal vesicle weight (% body weight) were considered to influence the conclusions. Thus, these parameters were downgraded in the publication bias. The outcomes of testis weight (g), relative testis weight (% body weight), epididymis weight (g), relative epididymis weight (% body weight), ventral prostate weight, AGD (mm), relative AGD (% body length), sperm count (×10⁶), daily sperm production (×10⁶), and serum testosterone (ng/ml) appeared to have consistent conclusions among the species subgroup analysis and were upgraded in the “cross-species” stage. The conclusions of the systematic review were translated into the final health effect on the basis of their rating outcome according to the OHAT manual. Finally, 13 outcomes were considered transformable to human health and had moderate or high confidence. The results of the confidence rating and health effect evaluation are shown in Table 4.

4 DISCUSSION

According to the results of our systematic review, TCDD exposure has a negative effect on the overall male reproductive system of rats and mice. Exposure to TCDD may cause atrophy of the testis (WMD: −0.035, 95% CI: −0.046 to −0.025) and epididymis (WMD: −0.029, 95% CI: −0.034 to −0.023), dysplasia of the ventral lobe prostate (WMD: −0.022, 95% CI: −0.027 to −0.017) and seminal vesicles (WMD: −0.041, 95% CI: −0.051 to −0.032), severely reduced sperm count (WMD: −35, 95% CI: −42.980 to −27.019), and other negative effects. In the subgroup analysis, most outcomes have the consistent conclusions across species, and the toxic effects vary due to different exposure time windows. For example, the testicular and the epididymal weights are sensitive to TCDD exposure during adolescence and adulthood, whereas sperm-related parameters are sensitive to TCDD exposure during pregnancy or adolescence. TCDD exposure causes a slight decrease in serum testosterone (WMD: −0.171, 95% CI: −0.269 to −0.073) and short AGD (WMD: −0.536, 95% CI: −0.269 to 0.073). The disruption of the
androgenic system may partly explain the adverse effect of TCDD on the male reproductive system. Previous human studies have shown that early exposure to TCDD can cause negative changes in male reproductive outcomes. Compared with nonexposure, exposure to TCDD prior to puberty reports significantly reduced sperm concentration ($53.6 \times 10^6$/ml, $p = 0.03$), and exposure during pregnancy leads to a significant decrease in the sperm concentration ($36.3 \times 10^6$/ml, $p = 0.002$) of male offspring (6). High peripubertal blood TCDD concentration is associated with low sperm count, which is similar to the result of our analysis (72). In animal studies, no significant change in relative testis weight (WMD: $-0.007$, 95% CI: $-0.035$ to $0.021$) is observed, which may be because TCDD causes developmental disorders in the male reproductive system and changes in bodyweight (14, 70).

Reports showed that a variety of compounds in the environment can induce adverse changes in the reproductive system (73). TCDD is considered a widespread environmental

FIGURE 2 | Forest plots of overall effects. Overall effects of TCDD and (A) sperm count ($\times 10^6$), (B) daily sperm production ($\times 10^6$), and (C) serum testosterone (ng/ml); (D) Total effect of TCDD and ventral prostate weight (g).
toxin that induces developmental and reproductive dysfunctions (74). TCDD exposure may result in numerous male reproductive toxic effects, such as spermatogenesis retardance and low testicular and sex organ weight (13). According to studies focusing on its toxicological mechanisms, TCDD is believed to exert its effects by binding to an intracellular transcription factor known as aryl hydrocarbon receptor (AhR) with high affinity (15). The treatment of wild-type rats with TCDD during pregnancy may result in gonadotropins and testicular steroid synthesis disorders in their offspring, but AhR knockout rats are not sensitive to this treatment (70). Compared with the control group, the wild-type mice treated with TCDD show a significant reduction in prostate protein markers and significantly shortened AGD, but these changes do not occur in AhR knockout mice (75). AhR activation can enhance the enzymes related to steroid metabolism, such as UDP-glucuronosyltransferase (UGT) 1A6/7, UGT1A8/9, and CYP1A2 activities, in pregnant rats and their offspring, thereby accelerating the metabolism of glucocorticoids and leading to decreased serum cortisol concentration. Decreased cortisol concentration causes growth hormone dysfunction and induces developmental disorders in the offspring (76). AhR can interfere with the synthesis of steroid hormones and indirectly damage the development of the male reproductive system. Moreover, AhR, as a nuclear receptor, can directly compete with the androgen receptor (AR), a nuclear receptor, to recruit cofactors or assemble the proteasome through the ubiquitination pathway for the direct degradation of the AR protein and the destruction of the normal physiological function of the AR pathway (77).

Considering that the male reproductive toxicity of TCDD is explained, researchers are also working to find possible protective agents. Recent studies found that resveratrol can rescue the toxic effects caused by TCDD to some extent. TCDD administration induces the reduction in the number of prostatic buds, which may cause prostate dysplasia, whereas this adverse effect is not significantly observed when TCDD is taken with resveratrol simultaneously (15). The reduction in Sertoli cell numbers and abnormal seminiferous tubule numbers caused by TCDD exposure can be protected by resveratrol (14). In addition to resveratrol, aminoguanidine can partially reverse the toxic effects of TCDD on male reproductive outcomes and reverse the toxic effect of TCDD on semen parameters (68). The reduction in serum testosterone concentration caused by TCDD can be rescued by the simultaneous administration of quinoline, and the histological morphology of the damaged seminiferous tubules can be remedied (13). In addition to the above agents, many plant extracts, such as protocatechuic acid, lycopene, ellagic acid, and ethanol extract of Allium sativum, have been shown to play a protective role in the male reproductive system damage caused by TCDD and may become potential clinical protective drugs in the future (12, 59, 61, 66) (Figure 3).

The effect of environmental endocrine disruptors on development and reproductive systems has attracted worldwide attention. In the past few years, male reproductive system diseases have become serious. The exposure to chemicals, such as bisphenol, pesticides, phthalates, and dioxin, are associated with poor reproductive outcomes (78). Evidence of male reproductive system damage due to exposure to TCDD, a well-known endocrine disruptor, has been confirmed in many animal experiments. More human observational studies need to be carried out to deeply understand the reproductive toxicity of TCDD. In addition, future research should focus on the reproductive toxicity mechanism of TCDD and other possible molecular pathways or targets. Researchers should find more effective protective drugs and study their protective mechanisms to provide solutions to the possible male reproductive system damage caused by TCDD.

To our knowledge, this is the first systematic review to quantitatively assess TCDD exposure and male reproductive system damage at different life stages and dosages. This review

TABLE 3 | Data of overall effects.

| D+L pooled WMD | [95% Conf. Interval] | % Weight |
|----------------|---------------------|----------|
| A              | -35.000             | (-42.980, -27.019) | 100      |
| Heterogeneity chi-squared = 11624.26 (d.f. = 61) p = 0.000 | I-squared (variation in WMD attributable to heterogeneity) = 99.5% | 100 |
| B              | -0.202              | (-0.254, -0.150)  | 100      |
| Heterogeneity chi-squared = 1992.72 (d.f. = 53) p = 0.000 | I-squared (variation in WMD attributable to heterogeneity) = 97.3% | 100 |
| C              | -0.171              | (-0.269, -0.073)  | 100      |
| Heterogeneity chi-squared = 1790.47 (d.f. = 61) p = 0.000 | I-squared (variation in WMD attributable to heterogeneity) = 96.6% | 100 |
| D              | -0.022              | (-0.027, -0.017)  | 100      |
| Heterogeneity chi-squared = 1990.02 (d.f. = 65) p = 0.000 | I-squared (variation in WMD attributable to heterogeneity) = 96.7% | 100 |

Overall effects of TCDD and A: sperm count (×10⁶), B: daily sperm production (×10⁹), and C: serum testosterone (ng/ml); D: Total effect of TCDD and ventral prostate weight (g).

Frontiers in Endocrinology | www.frontiersin.org November 2021 | Volume 12 | Article 696106
| TABLE 4 | Outcomes of confidence rating and health effect assessment. |
|---------|----------------------------------------------------------|
| **Factors decreasing confidence** | **Factors increasing confidence** |
| **Body of Evidence** | **Risk of Bias** | **Unexplained Inconsistency** | **Indirectness** | **Imprecision** | **Publication Bias** | **Magnitude** | **Dose Response** | **Residual Confounding** | **Consistency Across Species** | **Final Rating** | **Level of evidence for health effect** |
| Testis weight (g) | ++++ | ↓ | - | - | - | - | - | - | - | ↑ | ++++ High |
| Testes weight (g) | ++++ | ↓ | - | - | - | - | - | - | - | ↑ | ++++ Moderate |
| Relative testis weight (% body weight) | ++++ | ↓ | ↑ | ↑ | - | - | - | - | - | ↑ | +++ Inadequate |
| Relative testes weight (% body weight) | ++++ | ↓ | ↑ | - | - | - | - | - | - | ↑ | +++ Inadequate |
| Epididymis weight (g) | ++++ | ↓ | - | - | - | - | - | - | - | ↑ | ++++ High |
| Relative epididymis weight (% body weight) | ++++ | ↓ | - | - | - | - | - | - | - | ↑ | ++++ High |
| Ventral prostate weight (g) | ++++ | ↓ | - | - | - | - | - | - | - | ↑ | +++ Inadequate |
| Relative ventral prostate weight (% body weight) | ++++ | ↓ | - | - | - | - | - | - | - | ↑ | +++ Moderate |
| Seminal vesicle weight (g) | ++++ | ↓ | - | - | - | - | - | - | - | ↑ | ++ Low |
| Anogenital distance (mm) | ++++ | ↓ | - | - | - | - | - | - | - | ↑ | +++ Moderate |
| Relative anogenital distance (% body length) | ++++ | ↓ | - | - | - | - | - | - | - | ↑ | ++++ High |
| Sperm count ($\times 10^6$) | ++++ | ↓ | - | - | - | - | - | - | - | ↑ | ++++ High |
| Daily sperm production ($\times 10^6$) | ++++ | ↓ | - | - | - | - | - | - | - | ↑ | ++++ Moderate |
| Serum testosterone (ng/ml) | ++++ | ↓ | - | - | - | - | - | - | - | ↑ | ++++ High |
| Sperm motility (%) | ++++ | ↓ | - | - | - | - | - | - | - | ↑ | ++++ Moderate |
| Abnormal sperm (%) | ++++ | ↓ | - | - | - | - | - | - | - | ↑ | ++++ Moderate |
| Relative seminal vesicle weight (% body weight) | ++++ | ↓ | - | - | - | - | - | - | - | ↑ | ++ Low |
indicates that TCDD can cause damage to the male reproductive system of rodents. Although our conclusions are supported by many studies, some shortcomings remain. For example, the amount of data included is not large enough, and the design of animal experiments is generally not rigorous, which causes the overall quality of the included literature to become low. Moreover, the publication bias of several outcomes may affect the credibility of our conclusions. More rigorously designed studies should be carried out to enrich the evidence of TCDD male reproductive toxicity. In conclusion, multiple results of animal experiments confirm the male reproductive toxicity of TCDD, which may cause the human health problems.

5 CONCLUSIONS

TCDD may cause male reproductive system damage during pregnancy, adolescence, and adulthood. Notably, exposure during pregnancy causes significant semen abnormalities in male offspring, which may lead to decreased fertility of the next generation. For the health of the next generation of male reproductive systems and the ethnic reproduction of human beings, exposure during pregnancy should be taken seriously. More in-depth research on environmental reproductive poisons is needed.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

TZ: data curation, formal analysis, and writing—original draft. Xiz: data curation and formal analysis. XR: data curation and formal analysis. XuZ and JW: writing—review and editing. SW: funding acquisition, conceptualization, and resources. ZW: conceptualization and resources methodology. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the National Nature Science Foundation of China (No. 81800587).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2021.696106/full#supplementary-material

FIGURE 3 | Holistic view of TCDD environmental exposure and drug remedy.
Supplementary Figure 4 | Forest plots of Subgroup analysis. (A) Effect of TCDD and testes weight (g) by Species Subgroups; (B) Effect of TCDD and testes weight (g) by Species Subgroups; (C) Effect of TCDD and testes weight (g) by Exposure Windows Subgroups.

Supplementary Figure 5 | Forest plots of Subgroup analysis. (A) Effect of TCDD and testes weight (g) by Species Subgroups; (B) Effect of TCDD and testes weight (g) by Exposure Windows Subgroups; (C) Effect of TCDD and Testis Weight (g) by Dosage Levels Subgroups.

Supplementary Figure 6 | Forest plots of Subgroup analysis. (A) Effect of TCDD and testes weight (%body weight) by Species Subgroups; (B) Effect of TCDD and relative testes weight (%body weight) by Exposure Windows Subgroups; (C) Effect of TCDD and relative testes weight (%body weight) by Dosage Levels Subgroups.

Supplementary Figure 7 | Forest plots of Subgroup analysis. (A) Effect of TCDD and Relative testes weight (%body weight) by Species Subgroups; (B) Effect of TCDD and Relative testes weight (%body weight) by Exposure Windows Subgroups; (C) Effect of TCDD and Relative testes weight (%body weight) by Dosage Levels Subgroups.

Supplementary Figure 8 | Forest plots of Subgroup analysis. (A) Effect of TCDD and relative testis weight (%body weight) by Species Subgroups; (B) Effect of TCDD and relative testis weight (%body weight) by Dosage Levels Subgroups.

Supplementary Figure 9 | Forest plots of Subgroup analysis. (A) Effect of TCDD and relative epididymis weight (%body weight) by Species Subgroups; (B) Effect of TCDD and relative epididymis weight (%body weight) by Exposure Windows Subgroups; (C) Effect of TCDD and relative epididymis weight (%body weight) by Dosage Levels Subgroups.

Supplementary Figure 10 | Forest plots of Subgroup analysis. (A) Effect of TCDD and ventral prostate weight (g) by Species Subgroups; (B) Effect of TCDD and ventral prostate weight (g) by Exposure Windows Subgroups; (C) Effect of TCDD and ventral prostate weight (g) by Dosage Levels Subgroups.

Supplementary Figure 11 | Forest plots of Subgroup analysis. (A) Effect of TCDD and prostate weight (g) by Species Subgroups; (B) Effect of TCDD and prostate weight (g) by Exposure Windows Subgroups; (C) Effect of TCDD and prostate weight (g) by Dosage Levels Subgroups.

Supplementary Figure 12 | Forest plots of Subgroup analysis. (A) Effect of TCDD and relative ventral prostate weight (%body weight) by Species Subgroups; (B) Effect of TCDD and relative ventral prostate weight (%body weight) by Exposure Windows Subgroups; (C) Effect of TCDD and relative ventral prostate weight (%body weight) by Dosage Levels Subgroups.

Supplementary Figure 13 | Forest plots of Subgroup analysis. (A) Effect of TCDD and seminal vesicle weight (g) by Species Subgroups; (B) Effect of TCDD and seminal vesicle weight (g) by Exposure Windows Subgroups; (C) Effect of TCDD and seminal vesicle weight (g) by Dosage Levels Subgroups.

Supplementary Figure 14 | Forest plots of Subgroup analysis. (A) Effect of TCDD and anogenital distance (mm) by Species Subgroups; (B) Effect of TCDD and anogenital distance (mm) by Exposure Windows Subgroups; (C) Effect of TCDD and anogenital distance (mm) by Dosage Levels Subgroups.

Supplementary Figure 15 | Forest plots of Subgroup analysis. (A) Effect of TCDD and relative anogenital distance (%body length) by Species Subgroups; (B) Effect of TCDD and relative anogenital distance (%body length) by Exposure Windows Subgroups; (C) Effect of TCDD and relative anogenital distance (%body length) by Dosage Levels Subgroups.

Supplementary Figure 16 | Forest plots of Subgroup analysis. (A) Effect of TCDD and sperm count (×10⁶) by Species Subgroups; (B) Effect of TCDD and sperm count (×10⁶) by Exposure Windows Subgroups; (C) Effect of TCDD and sperm count (×10⁶) by Dosage Levels Subgroups.

Supplementary Figure 17 | Forest plots of Subgroup analysis. (A) Effect of TCDD and daily sperm production (×10⁶) by Species Subgroups; (B) Effect of TCDD and daily sperm production (×10⁶) by Exposure Windows Subgroups; (C) Effect of TCDD and daily sperm production (×10⁶) by Dosage Levels Subgroups.

Supplementary Figure 18 | Forest plots of Subgroup analysis. (A) Effect of TCDD and serum testosterone (ng/ml) by Species Subgroups; (B) Effect of TCDD and serum testosterone (ng/ml) by Exposure Windows Subgroups; (C) Effect of TCDD and serum testosterone (ng/ml) by Dosage Levels Subgroups.

Supplementary Figure 19 | Forest plots of Subgroup analysis. (A) Effect of TCDD and sperm motility (%) by Species Subgroups; (B) Effect of TCDD and sperm motility (%) by Exposure Windows Subgroups; (C) Effect of TCDD and sperm motility (%) by Dosage Levels Subgroups.

Supplementary Figure 20 | Forest plots of Subgroup analysis. (A) Effect of TCDD and abnormal sperm (%) by Species Subgroups; (B) Effect of TCDD and abnormal sperm (%) by Exposure Windows Subgroups; (C) Effect of TCDD and abnormal sperm (%) by Dosage Levels Subgroups.

Supplementary Figure 22 | Egger’s test for Publication Bias. (A) Egger’s test for Publication Bias of testis weight (g). Each point represents an individual comparison. (B) Egger’s test for Publication Bias of testes weight (g). Each point represents an individual comparison. (C) Egger’s test for Publication Bias of relative testes weight (%body weight). Each point represents an individual comparison. (D) Egger’s test for Publication Bias of relative testes weight (%body weight). Each point represents an individual comparison. (E) Egger’s test for Publication Bias of epididymis weight (g). Each point represents an individual comparison. (F) Egger’s test for Publication Bias of epididymis weight (%body weight). Each point represents an individual comparison. (G) Egger’s test for Publication Bias of ventral prostate weight (g). Each point represents an individual comparison. (H) Egger’s test for Publication Bias of prostate weight (g). Each point represents an individual comparison. (I) Egger’s test for Publication Bias of relative ventral prostate weight (%body weight). Each point represents an individual comparison. (J) Egger’s test for Publication Bias of seminal vesicle weight (g). Each point represents an individual comparison. (K) Egger’s test for Publication Bias of seminal vesicle weight (%body weight). Each point represents an individual comparison. (L) Egger’s test for Publication Bias of seminal vesicle weight (%body weight). Each point represents an individual comparison. (M) Egger’s test for Publication Bias of seminal vesicle weight (%body weight). Each point represents an individual comparison. (N) Egger’s test for Publication Bias of seminal vesicle weight (%body weight). Each point represents an individual comparison. (O) Egger’s test for Publication Bias of seminal vesicle weight (%body weight). Each point represents an individual comparison. (P) Egger’s test for Publication Bias of seminal vesicle weight (%body weight). Each point represents an individual comparison. (Q) Egger’s test for Publication Bias of seminal vesicle weight (%body weight). Each point represents an individual comparison. (R) Egger’s test for Publication Bias of seminal vesicle weight (%body weight). Each point represents an individual comparison.

Supplementary Figure 21 | Forest plots of Subgroup analysis. (A) Effect of TCDD and abnormal seminal vesicle weight (%body weight) by Species Subgroups; (B) Effect of TCDD and abnormal seminal vesicle weight (%body weight) by Exposure Windows Subgroups; (C) Effect of TCDD and abnormal seminal vesicle weight (%body weight) by Dosage Levels Subgroups.

Supplementary Table 1 | Topic statement and problem formulation.

Supplementary Table 2 | Data details of overall effects. (A) Overall effect of TCDD and sperm motility (%); (B) Overall effect of TCDD and abnormal sperm (%); (C) Overall effect of TCDD and anogenital distance (%body length); (D) Overall effect of TCDD and anogenital distance (%body length); (E) Overall effect of TCDD and seminal vesicle weight (g); (F) Overall effect of TCDD and prostate weight (g)
### Supplementary Table 4
Data details of overall effects. (A): Overall effect of TCDD and Testes Weight (g); (B): Overall effect of TCDD and Relative testes weight (%body weight); (C): Overall effect of TCDD and Relative testis weight (%body weight); (D): Overall effect of TCDD and Relative epididymis weight (%body weight)

### Supplementary Table 5
Data details of Subgroup analysis. (A): Effect of TCDD and testes weight (g) by Species Subgroups; (B): Effect of TCDD and testes weight (g) by Exposure Windows Subgroups; (C): Effect of TCDD and testes weight (g) by Dosage Levels Subgroups

### Supplementary Table 6
Data details of Subgroup analysis. (A): Effect of TCDD and testes weight (g) by Species Subgroups; (B): Effect of TCDD and testes weight (g) by Exposure Windows Subgroups; (C): Effect of TCDD and testes weight (g) by Dosage Levels Subgroups

### Supplementary Table 7
Data details of Subgroup analysis. (A): Effect of TCDD and relative testis weight (%body weight) by Exposure Windows Subgroups; (B): Effect of TCDD and relative testes weight (%body weight) by Exposure Windows Subgroups; (C): Effect of TCDD and relative testes weight (%body weight) by Dosage Levels Subgroups

### Supplementary Table 8
Data details of Subgroup analysis. (A): Effect of TCDD and and seminal vesicle weight (g) by Dosage Levels Subgroups; (B): Effect of TCDD and and seminal vesicle weight (g) by Species Subgroups; (C): Effect of TCDD and and seminal vesicle weight (g) by Dosage Levels Subgroups

### Supplementary Table 9
Data details of Subgroup analysis. (A): Effect of TCDD and and seminal vesicle weight (g) by Species Subgroups; (B): Effect of TCDD and and seminal vesicle weight (g) by Exposure Windows Subgroups; (C): Effect of TCDD and and seminal vesicle weight (g) by Dosage Levels Subgroups

### Supplementary Table 10
Data details of Subgroup analysis. (A): Effect of TCDD and sperm count (×10⁶) by Dosage Levels Subgroups; (B): Effect of TCDD and sperm count (×10⁶) by Species Subgroups; (C): Effect of TCDD and sperm count (×10⁶) by Exposure Windows Subgroups; (D): Overall effect of TCDD and and seminal vesicle weight (g) after 32 comparisons with the lowest weight dropped; (E): Overall effect of TCDD and and seminal vesicle weight (g) after 50% comparisons with the lowest weight dropped; (F): Overall effect of TCDD and and seminal vesicle weight (g) after 1 comparison with the lowest weight dropped

### Supplementary Table 11
Data details of Subgroup analysis. (A): Effect of TCDD and and seminal vesicle weight (g) by Dosage Levels Subgroups; (B): Effect of TCDD and and seminal vesicle weight (g) by Dosage Levels Subgroups; (C): Effect of TCDD and and seminal vesicle weight (g) by Dosage Levels Subgroups

### Supplementary Table 12
Data details of Subgroup analysis. (A): Effect of TCDD and and seminal vesicle weight (g) by Species Subgroups; (B): Effect of TCDD and and seminal vesicle weight (g) by Species Subgroups; (C): Effect of TCDD and and seminal vesicle weight (g) by Species Subgroups

### Supplementary Table 13
Data details of Subgroup analysis. (A): Effect of TCDD and and seminal vesicle weight (g) by Species Subgroups; (B): Effect of TCDD and and seminal vesicle weight (g) by Species Subgroups; (C): Effect of TCDD and and seminal vesicle weight (g) by Species Subgroups

### Supplementary Table 14
Data details of Subgroup analysis. (A): Effect of TCDD and and seminal vesicle weight (g) by Dosage Levels Subgroups; (B): Effect of TCDD and and seminal vesicle weight (g) by Dosage Levels Subgroups; (C): Effect of TCDD and and seminal vesicle weight (g) by Dosage Levels Subgroups

### Supplementary Table 15
Data details of Subgroup analysis. (A): Effect of TCDD and and seminal vesicle weight (g) by Species Subgroups; (B): Effect of TCDD and and seminal vesicle weight (g) by Species Subgroups; (C): Effect of TCDD and and seminal vesicle weight (g) by Species Subgroups

### Supplementary Table 16
Data details of Subgroup analysis. (A): Effect of TCDD and and seminal vesicle weight (g) by Species Subgroups; (B): Effect of TCDD and and seminal vesicle weight (g) by Species Subgroups; (C): Effect of TCDD and and seminal vesicle weight (g) by Species Subgroups

### Supplementary Table 17
Data details of Subgroup analysis. (A): Effect of TCDD and sperm count (×10⁶) by Species Subgroups; (B): Effect of TCDD and sperm count (×10⁶) by Species Subgroups; (C): Effect of TCDD and sperm count (×10⁶) by Dosage Levels Subgroups

### Supplementary Table 18
Data details of Subgroup analysis. (A): Effect of TCDD and daily sperm production (×10⁶) by Species Subgroups; (B): Effect of TCDD and daily sperm production (×10⁶) by Species Subgroups; (C): Effect of TCDD and daily sperm production (×10⁶) by Dosage Levels Subgroups

### Supplementary Table 19
Data details of Subgroup analysis. (A): Effect of TCDD and serum testosterone (ng/ml) by Dosage Levels Subgroups; (B): Effect of TCDD and serum testosterone (ng/ml) by Dosage Levels Subgroups

### Supplementary Table 20
Data details of Subgroup analysis. (A): Effect of TCDD and sperm motility (%) by Species Subgroups; (B): Effect of TCDD and sperm motility (%) by Species Subgroups; (C): Effect of TCDD and sperm motility (%) by Dosage Levels Subgroups

### Supplementary Table 21
Data details of Subgroup analysis. (A): Effect of TCDD and abnormal sperm (%) by Dosage Levels Subgroups; (B): Effect of TCDD and abnormal sperm (%) by Dosage Levels Subgroups

### Supplementary Table 22
Data details of Subgroup analysis. (A): Effect of TCDD and relative anogenital distance (%body length) by Dosage Levels Subgroups

### Supplementary Table 23
Outcomes of Egger’s test and results of the adjusted details. (A): Details of Egger’s test. Publication bias of tests weight (g) is detected; (B): Overall effect of TCDD and testes weight (g) after 1 comparison with the lowest weight dropped; (C): Details of Egger’s test for testes weight (g) after 1 comparison with the lowest weight dropped. No Publication Bias is detected; (D): Details of Egger’s test. Publication Bias of testes weight (g) is detected; (E): Overall effect of TCDD and testes weight (g) after 1 comparison with the lowest weight dropped. No Publication Bias is detected; (F): Details of Egger’s test for testes weight (g) after 1 comparison with the lowest weight dropped. No Publication Bias is detected; (G): Details of Egger’s test. Publication Bias of testes weight (g) is detected; (H): Overall effect of TCDD and testes weight (g) after 50% comparisons with the lowest weight dropped; (I): Details of Egger’s test for testes weight (g) after 50% comparisons with the lowest weight dropped. Publication Bias is detected; (J): Details of Egger’s test. No Publication Bias of relative testes weight (%body weight) is detected; (K): Details of Egger’s test. Publication Bias of epididymis weight (g) is detected; (L): Overall effect of TCDD and epididymis weight (g) after 32 comparisons with the lowest weight dropped; (M): Details of Egger’s test for epididymis weight (g) after 32 comparisons with the lowest weight dropped. No Publication Bias is detected; (N): Details of Egger’s test. No significant Publication Bias detected; (O): Details of Egger’s test. Publication Bias of relative testes weight (%body weight) is detected; (P): Overall effect of TCDD and testes weight (g) after 5 comparisons with the lowest weight dropped; (Q): Details of Egger’s test for testes weight (g) after 5 comparisons with the lowest weight dropped. No Publication Bias is detected; (R): Details of Egger’s test. No Publication Bias of relative testes weight (%body weight) is detected; (S): Details of Egger’s test. No Publication Bias of relative testes weight (%body weight) is detected; (T): Details of Egger’s test. No Publication Bias of relative testes weight (%body weight) is detected; (U): Details of Egger’s test. Calculation of publication bias detected; (V): Details of Egger’s test. No significant Publication Bias detected; (W): Details of Egger’s test. Calculation of publication bias detected; (X): Details of Egger’s test. Calculation of publication bias detected; (Y): Details of Egger’s test. No significant Publication Bias detected; (Z): Details of Egger’s test. Calculation of publication bias detected.

### Supplementary Table 24
Outcomes of Egger’s test and results of the adjusted details. (A): Details of Egger’s test. Publication Bias of tests weight (g) is detected; (B): Overall effect of TCDD and testes weight (g) after 50% comparisons with the lowest weight dropped; (C): Details of Egger’s test for testes weight (g) after 50% comparisons with the lowest weight dropped. Publication Bias is detected; (D): Details of Egger’s test. Publication Bias of anogenital distance (%body length) is detected; (E): Details of Egger’s test. Calculation of publication bias detected; (F): Details of Egger’s test. No significant Publication Bias detected; (G): Details of Egger’s test. No significant Publication Bias detected; (H): Details of Egger’s test. Calculation of publication bias detected; (I): Details of Egger’s test. Calculation of publication bias detected; (J): Details of Egger’s test. No significant Publication Bias detected; (K): Details of Egger’s test. Calculation of publication bias detected; (L): Details of Egger’s test. Calculation of publication bias detected; (M): Details of Egger’s test. Calculation of publication bias detected; (N): Details of Egger’s test. Calculation of publication bias detected; (O): Details of Egger’s test. Calculation of publication bias detected; (P): Details of Egger’s test. Calculation of publication bias detected; (Q): Details of Egger’s test. Calculation of publication bias detected; (R): Details of Egger’s test. Calculation of publication bias detected; (S): Details of Egger’s test. No significant Publication Bias detected; (T): Details of Egger’s test. No significant Publication Bias detected; (U): Details of Egger’s test. No significant Publication Bias detected; (V): Details of Egger’s test. No significant Publication Bias detected; (W): Details of Egger’s test. No significant Publication Bias detected; (X): Details of Egger’s test. No significant Publication Bias detected; (Y): Details of Egger’s test. Calculation of publication bias detected; (Z): Details of Egger’s test. No significant Publication Bias detected.
REFERENCES

1. Elsayed HYA, Borroto ET, Pliego AB, Dibarrat JA, Ramirez FR, Chagoyan JCV, et al. Sperm Quality in Mouse After Exposure to Low Doses of TCDD. Curr Topp Med Chem (2019) 19:931–43. doi: 10.2174/1568026619666619052009132

2. Bruner-Tran KL, Osteen KG. Developmental Exposure to TCDD Reduces Fertility and Negatively Affects Pregnancy Outcomes Across Multiple Generations. Reprod Toxicol (Elmsford NY) (2011) 31:344–50. doi: 10.1016/j.reprotox.2010.10.003

3. Patriot B, Sicilia A, Camus M. TCDD Toxicity Mediated by Epigenetic Mechanisms. Int J Mol Sci (2018) 19:4101. doi: 10.3390/ijms19124101

4. Mai X, Dong Y, Xiang L, Er Z. Maternal Exposure to 2,3,7,8-Tetrachlorodibenzo-P-Dioxin Suppresses Male Reproductive Functions in Their Adulthood. Hum Exp Toxicol (2020) 39:890–905. doi: 10.1177/096032720903489

5. U.S.E.P. Agency(EPA). Epa’s Reanalysis of Key Issues Related to Dioxin Toxicity and Response to NAS Comment, Volume 1. Environmental Protection Agency(EPA). Washington, DC: U.S. Environmental Protection Agency, 2012. EPA/600/R-10/038F.

6. Ekenazi B, Warner M, Brambilla P, Signorini S, Ames J, Mocarelli P. The Seveso Accident: A Look at 40 Years of Health Research and Beyond. Environ Int (2018) 121:71–84. doi: 10.1016/j.envint.2018.08.051

7. Bruner-Tran KL, Gnecco J, Ding T, Glore DR, Pensabene V, Osteen KG. Exposure to the Environmental Endocrine Disruptor TCDD and Human Reproductive Dysfunction: Translating Lessons From Murine Models. Reprod Toxicol (Elmsford NY) (2017) 68:59–71. doi: 10.1016/j.reprotox.2016.07.007

8. Rehman S, Usman Z, Rehman A, AlDraihem M, Rehman N, Rehman I, et al. Endocrine Disrupting Chemicals and Impact on Male Reproductive Health. Trans Andrology Urol (2018) 7:490–503. doi: 10.1037/tau.2018.05.17

9. Carlsen E, Giwercman A, Keiding N, Skakkebaek NE. Evidence for Decreasing Quality of Semen During Past 50 Years. BMJ (1992) 305:609. doi: 10.1136/bmj.305.6854.609

10. Agarwal A, Mulgund A, Hamada A, Chyatte MR. A Unique View on Male Fertility Around the Globe. Reprod Biol Endocrinol (2015) 13:37–7. doi: 10.1186/s12958-015-0032-1

11. Skakkebaek NE, Rajpert-De Meyts E, Buck Louis GM, Toppari J, Andersson A-M, Eisenberg ML, et al. Male Reproductive Disorders and Fertility Trends: Influences of Environment and Genetic Susceptibility. Physiol Rev (2016) 96:55–97. doi: 10.1152/physrev.00017.2015

12. Beyer A, Cifci O, Aydin M, Cakir O, Timurkaan N, Yilmaz F. Proteotoxic Effects of Reproductive Damage Caused by 2,3,7,8-Tetrachlorodibenzo-P-Dioxin (TCDD) in Male Rats. Andrologia (2012) 44 Suppl 1:454–61. doi: 10.1111/j.1439-0272.2011.01204.x

13. Cifci O, Aydin M, Ozdemir I, Vardi N. Quercetin Prevents 2,3,7,8-Tetrachlorodibenzo-P-Dioxin-Induced Testicular Damage in Rats. Andrologia (2012) 44:164–73. doi: 10.1111/j.1439-0272.2011.01126.x

14. Erthal RP, Siervo GEML, Silveira LTR, Scaranzi WR, Fernandes CA. Can Resveratrol Attenuate Testicular Damage in Neonatal and Adult Rats Exposed to 2,3,7,8-Tetrachlorodibenzo-P-Dioxin During Gestation? Reproduction Fertility Dev (2018) 30:442–50. doi: 10.1071/RD17180

15. Silveira LTR de M, Santos T, Camora LF, Pinheiro C, Anselmo-Franci JA, Domeniconi RF, et al. Protective Effect of Resveratrol on Urogenital Sinus and Prostate Development in Rats Exposed In Utero to TCDD (2,3,7,8-Tetrachlorodibenzo-P-Dioxin). Reprod Toxicol (Elmsford NY) (2019) 83:82–92. doi: 10.1016/j.reprotox.2018.06.012

16. Wesselink A, Warner M, Samuels S, Parigi A, Brambilla P, Mocarelli P, et al. Maternal Dioxin Exposure and Pregnancy Outcomes Over 30 Years of Follow-Up in Seveso. Environ Int (2014) 63:143–8. doi: 10.1016/j.envint.2013.11.005

17. Konishi K, Sasaki S, Kato S, Ban S, Washino N, Kajiwara J, et al. Prenatal Exposure to PCDDs/PCDFs and Dioxin-Like PCbs in Relation to Birth Weight. Environ Res (2009) 109:906–13. doi: 10.1016/j.envres.2009.07.010

18. Tuskimori K, Uchi H, Mitoma C, Yasukawa F, Chiba T, Todaka T, et al. Maternal Exposure to High Levels of Dioxins in Relation to Birth Weight in Women Affected by Yusho Disease. Environ Int (2012) 38:79–86. doi: 10.1016/j.envint.2011.08.010

19. Bjerke DL, Sommer RJ, Moore RW, Peterson RE. Effects of In Utero and Lactational 2,3,7,8-Tetrachlorodibenzo-P-Dioxin Exposure on Responsiveness of the Male Rate Reproductive System to Testosterone Stimulation in Adulthood. Toxicol Appl Pharmac (1994) 127:250–7. doi: 10.1006/tap.1994.1159

20. Gray LE, Osby JS, Kelce WR. A Dose-Response Analysis of the Reproductive Effects of a Single Gestational Dose of 2,3,7,8-Tetrachlorodibenzo-P-Dioxin in Male Long Evans Hooded Rat Offspring. Toxicol Appl Pharmac (1997) 146:11–20. doi: 10.1006/taap.1997.8223

21. Bjerke DL, Peterson RE. Reproductive Toxicity of 2,3,7,8-Tetrachlorodibenzo-P-Dioxin in Male Rats: Different Effects of In Utero Versus Lactational Exposure. Toxicol Appl Pharmac (1994) 127:241–9. doi: 10.1006/tap.1994.1158

22. NTP, (National Toxicology Program). Handbook for Conducting a Literature-Based Health Assessment Using OHAT Approach for Systematic Review and Evidence Integration. Office of Health Assessment and Translation, Division, National Toxicology Program, National Institute of Environmental Health Sciences (2015).

23. Pohjanvirta R, Tuomisto J, Vartiainen T, Rozman K, Han/Wistar Rats are Exceptionally Resistant to TCDD. J. Pharmacol Toxicol North Carolina: Research Triangle Park (1987) 60:145–50. doi: 10.1111/j.1600-0773.1987.tb01514.x

24. Al-Bayati ZAF, Walha ZZ, Stohs SJ. 2,3,7,8-Tetrachlorodibenzo-P-Dioxin (TCDD)-Induced Alterations in Lipid Peroxidation, Enzymes, and Divalent Cations in Rat Testis. Xenobiotica (1988) 18:1281–9. doi: 10.3109/0098288809042251

25. Chahoud I, Kroweck R, Schimmel A, Merker HJ, Neubert D. Reproductive Toxicity and Pharmacokinetics of 2,3,7,8-Tetrachlorodibenzo-P-Dioxin. 1. Effects of High Doses on the Fertility of Male Rats. Arch Toxicol (1989) 63:432–9. doi: 10.1007/BF00361444

26. Kleeman JM, Moore RW, Peterson RE. Inhibition of Testicular Steroidogenesis in 2,3,7,8-Tetrachlorodibenzo-P-Dioxin-Treated Rats: Evidence That the Key Lesion Occurs Prior to or During Pregnenolone Formation. Toxicol Appl Pharmac (1990) 106:112–25. doi: 10.1016/0040-8451(90)90111-7

27. Chahoud I, Hartmann J, Rane GM, Neubert D. Reproductive Toxicity and Pharmacokinetics of 2,3,7,8-Tetrachlorodibenzo-P-Dioxin. 3. Effects of Single Doses on the Testes of Male Rats. Arch Toxicol (1992) 66:367–72. doi: 10.1007/BF01973387

28. U.S.E.P. Agency(EPA). EPA’s Reanalysis of Key Issues Related to Dioxin Toxicity and Response to NAS Comment, Volume 1. Environmental Protection Agency(EPA). Washington, DC: U.S. Environmental Protection Agency, 2012. EPA/600/R-10/038F.
Spermatogenesis. *Toxicology* (1992) 76:103–18. doi: 10.1016/0300-483X(92)
90158-B

29. Mably TA, Bjørke DL, Moore RW, Gendon-Fitzpatrick A, Peterson RE. In *Utero* and Lactational Exposure of Male Rats to 2,3,7,8-Tetrachlorodibenzo-P-Dioxin. 3 Effects on Spermatogenesis and Reproductive Capability. *Toxicol Appl Pharmacol* (1992) 114:118–26. doi: 10.1016/0041-008X(92)90103-Y

30. Mably TA, Moore RW, Peterson RE. In *Utero* and Lactational Exposure of Male Rats to 2,3,7,8-Tetrachlorodibenzo-P-Dioxin. 1 Effects on Androgenic Status. *Toxicol Appl Pharmacol* (1992) 114:97–107. doi: 10.1016/0041-008X(92)90101-W

31. Gray LEfr, Kelce WR, Monesson O, Ostby JS, Birnbaum LS. Exposure to TCDD During Development Permanently Alters Reproductive Function in Male Long Evans Rats and Hamsters: Reduced Ejaculated and Epididymal Sperm Numbers and Sex Accessory Gland Weights in Offspring With Normal Androgenic Status. *Toxicol Appl Pharmacol* (1995) 131:108–18. doi: 10.1006/tapp.1995.1052

32. Roman BL, Sommer RJ, Shinomiya K, Peterson RE. In *Utero* and Lactational Exposure of the Male Rat to 2,3,7,8-Tetrachlorodibenzo-P-Dioxin: Impaired Prostate Growth and Development Without Inhibited Androgen Production. *Toxicol Appl Pharmacol* (1995) 134:241–50. doi: 10.1006/tapp.1995.1190

33. Sommer RJ, Ippolito DL, Peterson RE. In *Utero* and Lactational Exposure of the Male Holtzman Rat to 2,3,7,8-Tetrachlorodibenzo-P-Dioxin: Decreased Epididymal and Ejaculated Sperm Numbers Without Alterations in Sperm Transit Rate. *Toxicol Appl Pharmacol* (1996) 140:146–53. doi: 10.1006/tapp.1996.0027

34. Wilker C, Johnson L, Safe S. Effects of Developmental Exposure to Indole-3-Carbinol or 2,3,7,8-Tetrachlorodibenzo-P-Dioxin on Reproductive Potential of Male Rats in *Offspring*. *Toxicol Appl Pharmacol* (1996) 141:68–75. doi: 10.1016/S0041-008X(96)80010-X

35. Theobald HM, Peterson RE. In *Utero* and Lactational Exposure to 2,3,7,8-Tetrachlorodibenzo-P-Dioxin: Effects on Development of the Male and Female Reproductive System of the Mouse. *Toxicol Appl Pharmacol* (1997) 145:124–35. doi: 10.1006/tapp.1997.8173

36. Cooke GM, Price CA, Oko RJ, Effects of *In Utero* and Lactational Exposure to 2,3,7,8-Tetrachlorodibenzo-P-Dioxin (TCDD) on Serum Androgens and Steroidogenic Enzyme Activities in the Male Rat Reproductive Tract. *J Steroid Biochem Mol Biol* (1998) 67:347–54. doi: 10.1016/S0960-0760(98)00127-7

37. el-Sabeawy F, Wang S, Overstreet J, Miller M, Lasley B, Ennai E. Treatment of Rats During Pubertal Development With 2,3,7,8-Tetrachlorodibenzo-P-Dioxin Alters Both Signaling Kinase Activities and Epidermal Growth Factor Receptor Binding in the Testes and the Motility and Acrosomal Reaction of Sperm. *Toxicol Appl Pharmacol* (1998) 150:427–42. doi: 10.1006/tapp.1998.8246

38. Faqi AS, Dalserter PR, Merker HJ, Chahoud I. Reproductive Toxicity and Tissue Concentrations of Low Doses of 2,3,7,8-Tetrachlorodibenzo-P-Dioxin in Male Offspring Rats Exposed Throughout Pregnancy and Lactation. *Toxicol Appl Pharmacol* (1998) 150:383–92. doi: 10.1006/tapp.1998.8433

39. Roman BL, Timms BG, Prins GS, Peterson RE. In *Utero* and Lactational Exposure of the Male Rat to 2,3,7,8-Tetrachlorodibenzo-P-Dioxin Impairs Prostate Development. 2 Effects on Growth and Cytodifferentiation. *Toxicol Appl Pharmacol* (1998) 150:254–70. doi: 10.1006/tapp.1998.8395

40. Hamm JT, Sparrow BR, Wolf D, Birnbaum LS. In *Utero* and Lactational Exposure to 2,3,7,8-Tetrachlorodibenzo-P-Dioxin Alters Postnatal Development of Seminal Vesicle Epithelium. *Toxicol sciences: an Off J Soc Toxicol* (2000) 54:424–30. doi: 10.1093/toxsci/kf027

41. Kang KS, Li GX, Park JS, Lee BJ, Che JH, Tae JH, et al. Effect of Green Tea on Prostate and Seminal Vesicle in Rats Exposed to 2,3,7,8-Tetrachlorodibenzo-P-Dioxin. *J Microbiol Biotechnol* (2000) 10:281–6

42. Lin TM, Ko K, Moore RW, Buchanan DL, Cooke PS, Peterson RE. Role of the Aryl Hydrocarbon Receptor in the Development of Control and 2,3,7,8-Tetrachlorodibenzo-P-Dioxin-Exposed Male Mice. *J Toxicol Environ Health Part A* (2001) 64:327–42. doi: 10.1080/152873901131691312

43. Latchoumycandane C, Chitra KC, Mathur PP. The Effect of 2,3,7,8-Tetrachlorodibenzo-P-Dioxin on the Antioxidant System in Mitochondrial and Microsomal Fractions of Rat Testis. *Toxicology* (2002) 171:127–35. doi: 10.1016/S0300-483X(01)00563-7

44. Latchoumycandane C, Mathur PP. Effects of Vitamin E on Reactive Oxygen Species-Mediated 2,3,7,8-Tetrachlorodibenzo-P-Dioxin Toxicity in Rats. *Toxicol Appl Pharmacol* (2002) 22:345–51. doi: 10.1010/jat.866
61. Lee SC, Hwang SY, Kim SW, Kim SK. Ethanol Extract of Allium Sativum Attenuates Testicular and Liver Toxicity Induced by 2,3,7,8-Tetrachlorodibenzo-P-Dioxin in Rats. J Med Food (2009) 12:93–9. doi: 10.1089/jmf.2007.0670

62. Takeda T, Matsumoto Y, Koga T, Mutoh J, Nishimura Y, Shimaoe T, et al. Maternal Exposure to Dioxin Disrupts Gonadotropin Production in Fetal Rats and Imprints Defects in Sexual Behavior. J Pharmacol Exp Ther (2009) 329:1091–9. doi: 10.1124/jpet.109.151282

63. Dhanabalan S, D’Cruz SC, Mathur PP. Effects of Corticosterone and 2,3,7,8-Tetrachlorodibenzo-P-Dioxin on Epididymal Antioxidant System in Adult Rats. J Chem Mol Toxicol (2010) 24:242–9. doi: 10.1002/jctm.20032

64. Jin MH, Hong CH, Lee HY, Kang HJ, Han SW. Toxic Effects of Lactational Exposure to 2,3,7,8-Tetrachlorodibenzo-P-Dioxin (TCDD) on Development of Male Reproductive System: Involvement of Antioxidants, Oxidants, and P53 Protein. Environ Toxicol (2010) 25:1–8. doi: 10.1002/tox.20466

65. Dhanabalan S, Jubendradass R, Latha P, Mathur PP. Effect of Restraint Stress on 2,3,7,8-Tetrachloro Dibenzo-P-Dioxin Induced Testicular and Epididymal Toxicity in Rats. Hum Exp Toxicol (2011) 30:567–78. doi: 10.1177/0960327110376548

66. Sonmez M, Turk G, Ceribasi AO, Sakin F, Atessahin A. Attenuating Effect of Lycopene and Ellagic Acid on 2,3,7,8-Tetrachlorodibenzo-P-Dioxin-Induced Spermatozoa and Testicular Apoptosis. Drug Chem Toxicol (2011) 34:347–56. doi: 10.3109/01480545.2011.557382

67. Fujimoto N, Takagi A, Kanno J. Neonatal Exposure to 2,3,7,8-Tetrachlorodibenzo-P-Dioxin Increases the Mrna Expression of Prostatic Proteins in C57BL Mice. J Toxicol Sci (2013) 38:279–83. doi: 10.2131/jts.38.279

68. Oguz F, Ciftci O, Aydin M, Timurkaan N, Beytur A, Altintas R, et al. Aminoguanidine Prevents Testicular Damage-Induced-2,3,7,8-Tetrachlorodibenzo-P-Dioxin (TCDD) in Male Rats. Andrologia (2013) 45:225–31. doi: 10.1111/j.1439-0272.2012.01334.x

69. Sanabria M, Cucielo MS, Guerra MT, dos Santos Borges C, Banzato TP, Perobelli JE, et al. Sperm Quality and Fertility in Rats After Prenatal Exposure to Low Doses of TCDD: A Three-Generation Study. Reprod Toxicol (2016) 65:29–38. doi: 10.1016/j.reprotox.2016.06.019

70. Hattori Y, Takeda T, Nakamura A, Nishida K, Shioji Y, Fukumitsu H, et al. The Aryl Hydrocarbon Receptor is Indispensable for Dioxin-Induced Defects in Sexually-Dimorphic Behaviors Due to the Reduction in Fetal P53 Protein. J Biochem Mol Toxicol (2014) 28:96–101. doi: 10.1111/jbt.20332

71. Huang X, Xu X, Dai Y, Cheng Z, Zheng X, Huo X. Association of Prenatal Exposure to Polycyclic Aromatic Hydrocarbons With Birth Outcomes of Newborns. Sci Total Environ (2020) 723:138009. doi: 10.1016/j.scitotenv.2020.138009

72. Minguéz-Alarcón I, Sergeyev O, Burns JS, Williams PL, Lee MM, Korrick SA, et al. A Longitudinal Study of Peripubertal Serum Organochlorine Concentrations and Semen Parameters in Young Men: The Russian Children’s Study. Environ Health Perspect (2017) 125:460–6. doi: 10.1289/ehp.1501123

73. Guerrero-Bosagna CM, Skinner MK. Epigenetic Transgenerational Effects of Endocrine Disruptors on Male Reproduction. Semin Reprod Med (2009) 27:403–8. doi: 10.1055/s-0029-1237428

74. You YA, Mohamed EA, Rahman MS, Kwon WS, Song WH, Ryu BY, et al. 2,3,7,8-Tetrachlorodibenzo-P-Dioxin can Alter the Sex Ratio of Embryos With Decreased Viability of Y Spermatozoa in Mice. Reprod Toxicol (Elmsford N.Y.) (2018) 77:130–6. doi: 10.1016/j.reprotox.2018.02.011

75. Ohsako S, Fukuzawa N, Ishimura R, Kawakami T, WU Q, Nagano R, et al. Comparative Contribution of the Aryl Hydrocarbon Receptor Gene to Perinatal Stage Development and Dioxin-Induced Toxicity Between the Urogenital Complex and Testis in the Mouse. Biol Reprod (2010) 82:636–43. doi: 10.1095/biolreprod.109.080812

76. Hattori Y, Takeda T, Fujii M, Taura J, Ishii Y, Yamada H. Dioxin-Induced Fetal Growth Retardation: The Role of a Preceding Attenuation in the Circulating Level of Glucocorticoid. Endocrine (2014) 47:572–80. doi: 10.1007/s12020-014-0253-7

77. Brokken LJ, Giwercman YL. Gene-Environment Interactions in Male Reproductive Health: Special Reference to the Aryl Hydrocarbon Receptor Signaling Pathway. Asian J Andrology (2014) 16:89–96. doi: 10.4103/1008-682X.122193

78. Gomisiririki A, Mourikes VE, Flaws JA. Endocrine Disruptors in Water and Their Effects on the Reproductive System. Int J Mol Sci (2020) 21(6):1929. doi: 10.3390/ijms21061929

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.